JP2024522074A5 - - Google Patents
Info
- Publication number
- JP2024522074A5 JP2024522074A5 JP2023571772A JP2023571772A JP2024522074A5 JP 2024522074 A5 JP2024522074 A5 JP 2024522074A5 JP 2023571772 A JP2023571772 A JP 2023571772A JP 2023571772 A JP2023571772 A JP 2023571772A JP 2024522074 A5 JP2024522074 A5 JP 2024522074A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- construct
- vectors
- vector
- expressed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21174802 | 2021-05-19 | ||
| EP21174802.5 | 2021-05-19 | ||
| EP22158117 | 2022-02-23 | ||
| EP22158117.6 | 2022-02-23 | ||
| PCT/EP2022/063606 WO2022243448A1 (en) | 2021-05-19 | 2022-05-19 | Reprogramming of cells to type 1 conventional dendritic cells or antigen-presenting cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522074A JP2024522074A (ja) | 2024-06-11 |
| JP2024522074A5 true JP2024522074A5 (https=) | 2025-05-27 |
Family
ID=82067442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571772A Pending JP2024522074A (ja) | 2021-05-19 | 2022-05-19 | １型の通常型樹状細胞または抗原提示細胞への細胞のリプログラミング |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250186489A1 (https=) |
| EP (1) | EP4341384A1 (https=) |
| JP (1) | JP2024522074A (https=) |
| KR (1) | KR20240008332A (https=) |
| CA (1) | CA3218112A1 (https=) |
| IL (1) | IL308291A (https=) |
| WO (1) | WO2022243448A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025120097A1 (en) * | 2023-12-05 | 2025-06-12 | Asgard Therapeutics Ab | Rna-based strategies for dendritic cell reprogramming and uses thereof |
| WO2025198857A1 (en) * | 2024-03-20 | 2025-09-25 | The Regents Of The University Of California | Irf8-mediated reprogramming of the immune microenvironment in glioblastoma |
| WO2026003067A1 (en) * | 2024-06-25 | 2026-01-02 | Asgard Therapeutics Ab | Transcription factors and reprogramming modulators for reprogramming cells to cdc1 cells, compositions and methods thereof |
| WO2026003071A2 (en) * | 2024-06-25 | 2026-01-02 | Asgard Therapeutics Ab | Novel transcription factor combinations for immune cell reprogramming and related methods |
| WO2026009883A1 (ja) * | 2024-07-03 | 2026-01-08 | 慶應義塾 | 心筋ダイレクトリプログラミングのための組換えアデノ随伴ウイルスベクター |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101931403B1 (ko) * | 2011-09-23 | 2018-12-21 | 블루버드 바이오, 인코포레이티드. | 개선된 유전자 치료 방법 |
| WO2018185709A1 (en) * | 2017-04-05 | 2018-10-11 | Centro De Neurociencias E Biologia Celular | Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof |
-
2022
- 2022-05-19 IL IL308291A patent/IL308291A/en unknown
- 2022-05-19 WO PCT/EP2022/063606 patent/WO2022243448A1/en not_active Ceased
- 2022-05-19 EP EP22730733.7A patent/EP4341384A1/en active Pending
- 2022-05-19 US US18/560,525 patent/US20250186489A1/en active Pending
- 2022-05-19 JP JP2023571772A patent/JP2024522074A/ja active Pending
- 2022-05-19 KR KR1020237042428A patent/KR20240008332A/ko active Pending
- 2022-05-19 CA CA3218112A patent/CA3218112A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522074A5 (https=) | ||
| JP2020513191A5 (https=) | ||
| Gong et al. | Cancer cell reprogramming: a promising therapy converting malignancy to benignity | |
| Sanchez-Danes et al. | Deciphering the cells of origin of squamous cell carcinomas | |
| Buccini et al. | Cardiac progenitors derived from reprogrammed mesenchymal stem cells contribute to angiomyogenic repair of the infarcted heart | |
| BRPI0418805B1 (pt) | construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos | |
| CN104212802B (zh) | 一种肿瘤细胞广谱高活性启动子及其用途 | |
| JP6847977B2 (ja) | リプログラミング効果を用いて白血病を治療する方法 | |
| Li et al. | LncRNA HULC promotes epithelial and smooth-muscle-like differentiation of adipose-derived stem cells by upregulation of BMP9 | |
| JP2023506707A5 (https=) | ||
| Himal et al. | Evaluating Wharton’s Jelly‐Derived Mesenchymal Stem Cell’s Survival, Migration, and Expression of Wound Repair Markers under Conditions of Ischemia‐Like Stress | |
| WO2014114023A1 (zh) | 一种能够大规模并快速高纯度地诱导间充质干细胞转决定成造血干细胞的方法 | |
| Lopez et al. | Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses | |
| JP2023531092A (ja) | 悪性腫瘍の治療におけるメチオニン分解酵素遺伝子治療法の使用 | |
| Luo et al. | A Double‐Switch Cell Fusion‐Inducible Transgene Expression System for Neural Stem Cell‐Based Antiglioma Gene Therapy | |
| Ebrahimi | Cardiac progenitor reprogramming for heart regeneration | |
| Lai et al. | Use of human amnion epithelial cells as a feeder layer to support undifferentiated growth of mouse embryonic stem cells | |
| Rallabandi et al. | miRNA-mediated control of exogenous OCT4 during mesenchymal-epithelial transition increases measles vector reprogramming efficiency | |
| CN109055376B (zh) | 一种用于治疗hpv感染的药物及其应用 | |
| FI3607055T3 (fi) | Koostumuksia solujen uudelleenohjelmoimiseksi dendriittisoluiksi tai antigeeniä esitteleviksi soluiksi, niiden menetelmiä ja käyttötapoja | |
| CN106620703B (zh) | Gins2基因或蛋白的抑制剂在制备抗肿瘤药物中的应用 | |
| CN103952406B (zh) | 抑制人恶性脑胶质瘤增殖的靶向STAT3基因的siRNA及其表达载体和应用 | |
| CN103468725A (zh) | Pten基因过表达重组腺病毒载体的构建及应用 | |
| Lu et al. | EZH2 suppresses hepatocellular differentiation of mouse bone marrow mesenchymal stem cells | |
| CN115896112B (zh) | 靶向敲除人TMEM121基因的sgRNA，构建该基因缺失细胞株的方法及应用 |